Theranexus raises €3.6m

The fresh capital will be used to commence the clinical programme of the company's THN102 product for the treatment of narcolepsy.

Sofimac has invested via its Emergence Innovation 1 fund, which held its final close in March this year on €33.1m. The fund invests €300,000-1.35m in early-stage technology companies in certain French regions.

CEA, a founding shareholder in the company, has invested via its €38m Amorçage Technologique Investissement fund.

Company
Founded in 2013 and headquartered in Lyon, Theranexus is a developer of psychiatric and neurological treatments. Specifically, the company is developing adjuvant treatments for psychotropic medications.

People
Franck Mouthon is the co-founder and CEO of Theranexus. Auriga investment director Emmanuelle Coutanceau has joined the company's advisory board alongside Sofimac investment director Cécile Thébault, CEA investment director Celia Hart and Rhône-Alpes associate Gwenaël Hamon.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Early-stage
• France
• Healthcare
• Sofimac
• CEA Investissement
• France